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expansion. Implications for combined chemotherapy
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Plata, La Plata, Argentina
ABSTRACT
Mitosis has been traditionally considered a metabolically inactive phase. We have previously
shown, however, that extensive alterations in lipids occur as the cells traverse mitosis, including
increased de novo fatty acid (FA) and phosphatidylcholine (PtdCho) synthesis and decreased
lysophospholipid content. Given the diverse structural and functional properties of these lipids,
we sought to study their metabolic fate and their importance for cell cycle completion. Here we
show that FA and PtdCho synthesized at the mitotic exit are destined to the nuclear envelope.
Importantly, FA and PtdCho synthesis, but not the decrease in lysophospholipid content, are
necessary for cell cycle completion beyond G2/M. Moreover, the presence of alternative pathways
for PtdCho synthesis renders the cells less sensitive to its inhibition than to the impairment of FA
synthesis. FA synthesis, thus, represents a cell cycle-related metabolic vulnerability that could be
exploited for combined chemotherapy. We explored the combination of fatty acid synthase
(FASN) inhibition with agents that act at different phases of the cell cycle. Our results show that
the effect of FASN inhibition may be enhanced under some drug combinations.
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Cancer cell metabolic reprogramming includes
increased de novo lipogenesis to support cellular
growth and proliferation. This has roused the
interest of lipogenic enzymes as putative targets
for cancer treatment [1–4]. Although the impor-
tance of lipogenesis for cell proliferation and sur-
vival is well established, much less is known about
its coordination with cell cycle progression.
Phosphatidylcholine (PtdCho), the main phos-
pholipid inmammalian cells, is synthesized through-
out the cell cycle but the bulk net accumulation is
thought to occur at S phase [5–7]. De novo synthesis
and degradation of different phospholipids has also
been documented at mitosis [8–11]. During mitosis
and cytokinesis major processes involving mem-
brane expansion and remodelling occur. In regards
to the plasma membrane, cytokinesis entails an
increase surface area to volume ratio and profound
curvature changes at the cleavage furrow. Another
membrane structure that undergoes major changes
at the mitotic exit is the nuclear envelope (NE),
which is reassembled and expanded at telophase.
Although these processes presume changes in mem-
brane lipids, little is known about lipidmetabolism at
G2 and M phases of the cell cycle.
Different mechanisms have been reported to
account for the increase in plasma membrane sur-
face upon cytokinesis, including the smoothing of
stored external surface as microvilli [12,13] and the
recycling of previously internalized plasma mem-
brane back to the cell surface [14]. Phospholipid
synthesis may be required to compensate for the
increased surface area to volume ratio after cytokin-
esis. In addition to the requirements for bulk mem-
brane expansion, localized synthesis or changes in
composition of lipids may be important for struc-
tural membrane changes. In this regard, it has been
reported that a localized production of phosphatidy-
linositol 4,5-bisphosphate and translocation of phos-
phatidylethanolamine to the cell surface at the
cleavage furrow are required for proper cytokinesis
[15,16]. Extensive membrane reorganization is also
observed upon reassembly and expansion of the NE
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[17]. The importance of lipid composition under-
lying membranes alterations during cell division is
becoming apparent [18]; their function and regula-
tion are, however, poorly understood.
We have previously shown that extensive altera-
tions in lipids occur as the cells traverse mitosis.
Lysophospholipid levels (product of phospholipid
hydrolysis) decreases drastically from G2/M to G1
phase while de novo PtdCho synthesis increases, sug-
gesting that enhanced membrane production is con-
comitant to a decrease in its turnover. In addition,
fatty acid (FA) synthesis and incorporation intomem-
branes is increased upon cell division, paralleling
acetyl-CoA carboxylase activity (the rate-limiting
enzyme of the pathway). Importantly, the inhibition
of fatty acid synthesis induces cell cycle arrest at G2/M,
before anaphase, in a variety of cancer cells, despite the
presence of abundant fatty acids in the media [19].
Our results showed that de novo FA synthesis is essen-
tial for cell cycle completion. The function and cellular
fate of these lipids are, however, largely unknown.
Given that the nuclear and plasma membranes
undergo profound structural changes at the mitotic
exit, we sought to study the fate of these newly synthe-
sized lipids and the biological consequences of their
alteration. We also evaluated the effect of the com-
bined inhibition of lipogenesis and anticancer agents
on cellular proliferation in vitro. A better knowledge of
the “lipogenic checkpoint” at G2/M may help to
understand the metabolic requirements during the
cell cycle and to design rational schedules of combined
therapies to treat cancer.
Materials and methods
Materials
The alkyl-lysophospholipid edelfosine (1-Octadecyl-
2-methylglycero-3-phosphorylcholine SML0332),
propidium iodide, ribonuclease A, C75, thymidine,
etoposide, CI-976, choline metabolites used for stan-
dards, fatty acid free bovine serum albumin (BSA),
nocodazole, Hoechst 33342, and other reagents were
purchased from Sigma. [1-14C]Acetate, sodium salt,
59 mCi/mmol and [methyl-3H]choline chloride,
83 Ci/mmol, were purchased from Amersham.
Lysopalmitoyl phosphatidylcholine-L-1-[palmitoyl-
1-14C], 56 mCi/mmol, was purchased from New
England Nuclear. Staurosporine and 5-fluorouracil
were kind gifts from Dr Ezequiel Lacunza (National
University of La Plata, Argentina). Tissue culture
material was purchased from Greiner BioOne, low
and high glucose Dulbecco's Modified Eagle
Medium (DMEM), vitamins and penicillin/strepto-
mycin were purchased from Gibco. Fetal bovine
serum (FBS) was purchased from Natocor and lipid
standards from Nu-Check Prep. Alexa 488-azide was
purchased from Invitrogen. 5-Bromo-2′-
deoxyuridine (BrdU) was purchased from UpState
and FITC-conjugated anti-BrdU antibody was pur-
chased from BD Biosciences. Propargyl-choline was
a kind gift from Dr Adrian Salic (Harvard University,
USA). Crystal violet was purchased from Biopack.
ON-TARGET Plus small interfering RNA (siRNA)
targeting FASN, CTα or a non-targeting pool were
purchased from Dharmacon. Lipofectamine
RNAiMax and SuperSignalWest Picowere purchased
from Thermo-Fisher. PVDF membrane was pur-
chased from GE Healthcare Amersham.
Cell culture and synchronization
HeLa cells (from ATCC) were routinely grown in
DMEM supplemented with 10% FBS, 100 units peni-
cillin/ml and 100 µg streptomycin/ml (P/S), 37°C, 5%
CO2 and 100% humidity. One week prior to seeding
for the experiments, the media was changed to low
glucose DMEM (5 mM), which approximates normal
blood glucose levels in vivo, supplemented with 10%
FBS and P/S. Unless otherwise stated, 3.2 × 105 HeLa
cells were seeded in 60mmdishes and allowed to grow
for 24 h. For microscopy studies, the cells were grown
on glass coverslips. For the subcellular fractionation
assays, 5 × 105 cells were seeded in 100 mm dishes.
Cells were synchronized at the G1/S boundary by
double thymidine block (2TB) or at mitosis by thymi-
dine-nocodazole block as previously described [20].
Cell number and viability
Cell number was quantitated by hemocytometer
and viability was estimated by Trypan-Blue exclu-
sion or cleaved PARP content (by Western Blot).
Alternatively, total cell mass was assessed by
Crystal violet staining as described previously [21].
Transfection
The cells were transfected with ON-TARGET
Plus siRNA (Dharmacon) targeting human
fatty acid synthase (FASN), CTP:phosphocholine
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cytidylyltransferase (PYCT1A, CTα) or a Non-
Targeting pool (NT) at 10 nM for 4–6 h using
Lipofectamine RNAiMAX Transfection Reagent
(ThermoFisher) according to the manufacturers’
instructions. The cells were harvested at 48 h and the
knockdown was confirmed by Western Blot. siRNA
targeting sequences are provided in Supplemental
Table 3.
Metabolic labelling and lipid analysis
Cells were synchronized as described above by 2TB,
released from the blockage in fresh media for 8 h.
The cells were labelled with 1–2 μCi/dish (0.5 μCi/
ml) of [1-14C] Acetic acid for 2 h in growing media.
Subcellular fractions were obtained as described
below. The lipids were extracted from each fraction
as described by Bligh & Dyer [22] and analysed as
described in [23].
CTP:phosphocholine cytidylyltransferase activ-
ity was estimated as described by Bagnato et al
[24]. Briefly, the cells were incubated with 1 μCi/
ml [methyl-3H]choline for 4 h. The lipids were
extracted as described by Bligh & Dyer and the
aqueous phases were dried, dissolved in water,
spotted on silica gel chromatoplates, and resolved
with 0.6% sodium chloride, methanol, 30% ammo-
nium hydroxide; 50:50:5 (by vol). Pure choline,
CDP-choline, phosphocholine, acetyl-choline and
betaine standards were run in parallel. The stan-
dards were visualized by charring and the radiola-
belled choline metabolites were scrapped from the
chromatoplate and quantified by scintillation
counting.
LysoPtdCho acyl-transferase activity was esti-
mated by conversion of Lysopalmitoyl phosphatidyl-
choline-L-1-[palmitoyl-1-14C] to [14C] PtdCho.
Briefly, the cells were incubated with LysoPtdCho
(previously purified by thin layer chromatography –
TLC- to remove hydrolysed palmitate) in FBS-free
DMEM with 0.5% FA-free bovine serum albumin
for 2 h. The lipids were extracted as described and
resolved by TLC in chloroform:methanol:acetic acid:
water (50:37.5:3.5:2 by vol). The radiolabelled meta-
bolites were scrapped from the chromatoplate and
their radioactivity quantified by scintillation
counting.
The subcellular fate of the de novo synthesized
PtdCho was assessed by propargyl-choline accord-
ing to [25]. Briefly, cells were plated on coverslips
and synchronized at the G1/S boundary as
described above by 2TB. The cells were labeled
with 2 mM propargyl-Cho bromide in complete
media for 2 h between 8 and 10 h after release.
Alternatively, the cells synchronized at mitosis by
nocodazole block as previously described were
labeled with 2 mM propargyl-Cho bromide in
complete media for 2 h after release. The samples
were processed for microscopy as described below.
Flow cytometry
Cell cycle distribution was analysed as described
previously [19] in a FACSCalibur or Accuri C6Plus
cytometer (Becton Dickinson) and FlowJo software.
At least ten thousand events were acquired per
sample.
Subcellular fractionation
Synchronized or asynchronously growing cells
were trypsinized, pelleted by centrifugation and
rinsed with phosphate buffered saline. The cells
were resuspended in isolation medium (250 mM
sucrose, 1 mM EGTA-Tris, 2 mM MgCl2, 10 mM
HEPES-Tris pH 7.4 as described in [26]), and
centrifuged to remove salts. The pellets were resus-
pended in a slightly hypotonic buffer (isolation
medium containing 125 mM sucrose), incubated
on ice for 15 min and homogenized with a 27 G
needle. The cell lysates were brought to isotonicity
(250 mM sucrose) and centrifuged at 4ºC for 1 h at
170,000 g. The supernatant (cytosolic fraction) was
set aside and the pellets were resuspended in 1ml
isolation medium containing 30% sucrose. The
samples were placed on a discontinuous (30/35/
40/70% w/v) sucrose-isolation media gradient and
centrifuged at 100,000 g for 17 h at 4ºC in a (SW
60Ti Beckman Coulter Ultracentrifuge) [27]. An
aliquot of the fractions collected (1 to 8 from the
top to the bottom) was used for Western Blot. The
lipids were extracted from each fraction as
described previously. The sucrose concentration
across the gradient was verified by refractometry.
The purity and distribution of the subcellular frac-
tions across the gradient were assessed by immu-
noblotting as described below.
Immunofluorescence and fluorescence microscopy
Cells incubated with propargyl-Choline and pro-
cessed as described above, were fixed with 4%
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p-formaldehyde 4% sucrose in phosphate buffered
saline (PBS), were let to react with 10 µM Alexa488-
azide, 1 mM CuSO4, 100 mM Tris pH8.5 and 50 mM
ascorbic acid for 30 min at room temperature and
washed 3 times with PBS. After counterstaining with
Hoechst, the coverslips were mounted onto micro-
scope glass slides with MOWIOL and stored at 4°C
until analysis. The cells were imaged by fluorescence
microscopy and phase contrast in an Olympus BX51
microscope. Alternatively, propargyl-Cho-Alexa 488-
labeled cells were incubated with 3% BSA in PBS 0.1%
(v/v) Triton X-100 at room temperature for 60 min,
followed by incubation at 37°C for 60 min with 1:100
mouse anti-Lamin A/C antibody (Millipore) a kind
gift fromDr. Nicolas Favale (Buenos Aires University,
Argentina). Primary interactions were detected using
a 1:500 F(ab´)2 fragment of goat anti-mouse IgG
conjugated with Cy3 (Jackson ImmunoResearch)
[28]. ER was labeled with 1:250 Alexa 647-
conjugated concanavalin A (Molecular Probes) kindly
provided by Dr. Nicolas Favale (Buenos Aires
University, Argentina) as described in [28]. Anti-CT
α for immunofluorescence studies was a kind gift
from Dr. Rosemary Cornell (Simon Fraser
University, Canada). The coverslips were mounted
on microscope glass slides with MOWIOL and stored
at 4°C until analyzed. Images of confocal immuno-
fluorescence were obtained with an Olympus FV1000
confocal microscope and analyzed with ImageJ soft-
ware. Manders’s overlap coefficient was obtained
using JaCoP plugin on Image J [29]. The Costes
thresholding method was used to determine the
threshold values [30]. At least 20 cells (n = 20) were
analyzed in three different experiments.
Immunoblotting
Cells were lysed in 1% NP-40 buffer with pro-
tease inhibitors. The lysates were cleared by cen-
trifugation and 20–50 μg of protein, resolved on
12% Tris-glycine SDS-polyacrylamide gels, were
transferred to PVDF membrane. The following
antibodies were used: anti-Cyclin B1, anti-CTα,
anti-PARP, anti-Cyclin D1, anti-Caspase 3, anti-
ERp72 and anti-Vinculin (Cell Signaling
Technology), anti-FASN (BD Transduction
laboratories), anti-β-actin (Sigma), anti-Histone
H3 (Abcam). Anti Na/K ATPase and anti-Tom
20 (Santa Cruz Biotechnology) were kind gift
from Dr. Cecilia Mundiña (National University
of La Plata, Argentina) and Dr. Jimena Martinez
(Buenos Aires University, Argentina), respec-
tively. Anti-CTβ 1N was kindly provided by
Dr Claudia Banchio (Institute of Molecular and
Cell Biology of Rosario, Argentina). The densito-
metric analysis was carried out using Quantity
One Software (Bio-Rad)
Protein quantification
Total cellular protein content was quantified by
the Bradford protein assay using bovine serum
albumin as standard.
Drug treatment and analysis
Except for CI-976, the cells were incubated with
different drugs for 24 h in full low glucose DMEM.
For the experiments with CI-976, the cells were
washed and incubated with FBS-depleted DMEM
since serum has been shown to inhibit the action
of CI-976 [31]. Twenty-four hour depletion of FBS
has no effect on cell cycle progression in HeLa
cells [19]. For the drug combinations, the cells
were incubated simultaneously with the indicated
concentrations for 24 h and processed for crystal
violet dye assay. The fraction affected (Fa) was
calculated as described by Topaly et al [32] and
the combination index (CI) was calculated with
CompuSyn Software and interpreted as described
by Ichite et al. [33]. The CI is a quantitative mea-
sure of the degree of interaction between different
drugs. If CI = 1, it denotes additivity; if CI > 1, it
denotes antagonism; if CI < 1, it denotes syner-
gism. Only the drugs that showed an R squared ≥
0.8 for dose-effect as single agents were used for
combination assays. Alternatively, the cells were
transfected with siRNA targeting FASN or a Non-
targeting pool for 48 h. Twenty-four hours prior
the harvesting, the cells were incubated with 80
μM etoposide or vehicle.
Statistical analysis
Unless otherwise stated, the experiments were per-
formed at least twice with 2–4 biological replicates
per group per experiment. Statistically significant
differences were assessed by unpaired t-test or two
way ANOVA with Tukey's multiple comparison
test. A representative experiment is shown as
mean ± S.D. A P-value < 0.05 was considered
statistically significant.
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Results
De novo synthesized fatty acids are directed to
the nuclear envelope (NE) at the mitotic exit
De novo FA synthesis increases as the cells traverse
mitosis [19]. In order to assess the subcellular fate
of this newly synthesized FA, we combined meta-
bolic labeling of synchronized cells with subcellu-
lar fractionation by ultracentrifugation. The
synchronized cells traversed mitosis from 8 to
10 h after the thymidine blockage (2TB) release
as previously reported [19] and evidenced by
Cyclin B1 levels (Supplemental Figure 1.A). Thus,
the cells were incubated with [1-14C] acetate from
8 to 10 h after the 2TB to assess their subcellular
fate. The distribution of the subcellular fractions
was analyzed by Western Blot using specific mar-
kers (Figure 1(a) and Supplemental Figure 1.B).
The plasma membrane marker was predominantly
in the upper fractions of the gradient (1 to 4). The
mitochondria marker was found mainly in fraction
6 whereas the endoplasmic reticulum (ER) and
nucleus markers were restricted to the bottom of
the gradient (fractions 7 and 8). A similar distri-
bution of the markers was obtained from the
asynchronous population (data not shown). In all
fractions, most of the acetate-derived label was
found in phospholipids (mainly PtdCho) (results
not shown). Cells traversing mitosis incorporated
most of the [1-14C] acetate in lipids associated to
fractions 6–8 and only reduced amounts in the
plasma membrane-associated fractions of the gra-
dient (Figure 1(b)). We found a similar acetate
incorporation into mitochondrial fraction in syn-
chronized and asynchronously growing cells
(Supplemental Figure 1.C), consistent with pre-
vious reports showing continuous growth of mito-
chondrial membranes throughout the cell cycle
[34]. Thus, these results suggests that the increased
de novo synthesized FA at the mitotic exit are
directed to the NE.
Newly synthesized PtdCho colocalizes with ER
and nuclear membrane markers
We previously showed that de novo PtdCho synth-
esis increases at the mitotic exit [19]. To evaluate the
subcellular distribution of these newly synthesized
phospholipids, we used a choline analog that, by
means of a propargyl group, can be detected using
a click chemistry reaction [25]. Newly synthesized
choline-containing lipids were incorporated in the
a b
Figure 1. De novo synthesized lipids are directed to the nuclear envelope upon mitosis. Synchronized HeLa cells were incubated for
2 h (from G2/M) with [
14C]acetate. Homogenates were centrifuged for 1 h at 170,000 g 4°C. A sucrose gradient was assembled with
the resuspended pellet and centrifuged for 17 h at 100,000 g at 4°C. Fractions named 1 to 8 from top to bottom of the gradient were
set-apart. An aliquot of the gradient fractions was used for Western Blot. Markers for plasma membrane (Na+/K+ ATPase),
mitochondria (Tom 20), endoplasmic reticulum (ERp72) and nucleus (Histone H3) were assessed in each fraction. The percentage
of each marker signal across the gradient was calculated (a). The remaining sample was used for lipid extraction. The lipid-associated
radioactivity was quantitated by scintillation counting in each fraction (b).
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nuclear/perinuclear region (Figure 2), consistent
with a nuclear membrane-ER distribution. To
study more precisely the localization of these lipids,
we performed colocalization studies by confocal
microscopy. Propargil-choline containing lipids
colocalized with markers of the ER (Figure 3) and
nuclear membranes (Figure 4) (Manders overlap
coefficients (r) 0.86 ± 0.05 and 0.84 ± 0.07, respec-
tively) further supporting the evidence that the de
novo synthesized phospholipids at the mitotic exit
are directed to the NE.
Impaired de novo PtdCho synthesis does not
affect cell cycle progression
We previously showed that FASN inhibitor C75
arrested the cells at G2/M [19]. FASN knockdown
with different siRNAs recapitulated the phenotype
(evidenced by increased cyclin B1 levels)
(Supplemental Figure 2), supporting our previous
results and ruling out a non-specific effect of the
small molecule inhibitor. Given that FA are used
for phospholipids production, we evaluated whether
the de novo PtdCho synthesis (the Kennedy path-
way) was necessary to complete the cell cycle. To do
this, we knocked downCTα, the rate-limiting enzyme
in the pathway, with siRNAs. All four siRNA
sequences targeting CTα decreased the enzyme levels
significantly (Figure 5(a) and Supplemental Figure 3.
A) compared to the non-targeting (NT) pool. Cyclin
B1 was not changed in CTα knockdown cells (Figure
5(a) and Supplemental Figure 3.B). This was con-
firmed by a flow cytometry analysis that showed that
CTα knockdown did not alter cell cycle distribution
(Figure 5(d)) albeit both the CTα levels (Figure 5(b))
and its activity -assessed in a parallel sample- (Figure
5(c)) were decreased. Apoptosis and ploidy were not
affected either (not shown). This lack of response was
not due to a compensatory increase in CTβ isoform
(Supplemental Figure 3.C).
Simultaneous inhibition of PtdCho synthesis and
lysophospholipid acylation induces apoptosis
and G2/M arrest
An alternative route for PtdCho synthesis is
LysoPtdCho acylation. LysoPtdCho acylation can
supply PtdCho for membrane synthesis and cell
division [35]. LysoPtdCho content is high at G2/M
and decreases as the cells reach G1 [19]. Twenty-
four hours incubation with CI-976, an inhibitor of
lysophospholipid acyltransferases, decreased cell
number in a concentration-dependent manner
(Figure 6(a)), inducing apoptosis at the highest
concentration tested (12.5 μM, data not shown).
At 2.5 μM CI-976 decreased LysoPtdCho acylation
(Figure 6(b)) but it did not cause G2/M arrest.
Rather, an increase in cells at G1 was detected by
flow cytometry (Figure 6(c)) and a concomitant
decrease in cyclin B1 (Figure 6(d)). At this
a
c d g h
b e f
Figure 2. Cellular distribution of choline at the mitotic exit. HeLa cells, synchronized by 2TB (a–d) or nocodazole (e–h), were
incubated with 2 mM prop-Cho in complete media for 2 h (G2/M to G1 transition). The cells were fixed and reacted with 10 µM azide-
Alexa488 (c and g). After counterstaining with Hoechst (b and f), the cells were imaged by fluorescence microscopy and phase
contrast at 100X in an Olympus BX51 microscope. (a) and (e), bright field; (d) and (h), merged.
6 L. RODRIGUEZ SAWICKI ET AL.
concentration, CI-976 did not induce apoptosis,
evidenced by the absence of significant cleaved-
Poly ADP-ribose polymerase (PARP) (Figure
6(d)).
The alkyl-lysophospholipid edelfosine inhibits
both PtdCho synthesis and LysoPtdCho acylation
[36,37]. Treatment of HeLa cells with edelfosine up
to 20 μM decreased cell number and viability in
a dose-dependent manner (Figure 7(a) and not
shown). At 2.5 μM, cell number was reduced to
a greater extent than viability, suggesting arrest of
the cell cycle. Indeed, we observed cell cycle arrest at
G2/M, as evidenced by cyclin B1 accumulation and
flow cytometry analysis (Figure 7(b,c)). Importantly,
impairment in lipid metabolism was observed at
concentrations that did not affect cell cycle or viabi-
lity, as assessed by cyclin B1, D1, cleaved PARP and
cleaved caspase 3 levels (Supplemental Figure 4 and
results not shown) and flow cytometry (Figure 7(c)),
supporting the idea that the enzyme inhibition is the
cause (not the consequence) of the changes in cell
proliferation.
Our data imply that it is the synthesis of PtdCho
rather than the decrease in the LysoPtdCho con-
tent observed as the cells transverse mitosis [19],
which is important for cell cycle completion.
Taken together, these results suggest that both
the LysoPtdCho acylation and the Kennedy path-
way can equally contribute to the synthesis of the
PtdCho required for cell cycle completion.
Relevance of the mitotic lipogenic checkpoint for
the design of combined drug treatment
To test if the “lipogenic checkpoint” at G2/M can be
exploited for combined therapy, we treated the cells
with the FASN inhibitor, C75, and different agents
that act mainly on one phase of the cell cycle.We used
staurosporine, 5-fluorouracil and etoposide for G1,
S and G2/M arrest, respectively. The response of
HeLa cell line to single agents is shown in
c d
ba
Figure 3. Choline containing lipids synthesized as the cells
transverse mitosis colocalize with ER membrane marker. HeLa
cells, synchronized by 2TB and released for 8 h, were incubated
with 2 mM prop-Cho for 2 h. The cells were fixed and processed
for immunofluorescence with Alexa 488-azide (b) and Alexa
647-conjugated concanavalin A (c) and analyzed by confocal
microscopy (Olympus FV1000 microscope). (a) Hoechst stain-
ing; (d) merged.
a b c d
Figure 4. Choline containing lipids synthesized as the cells transverse mitosis colocalize with nuclear membrane marker. HeLa cells,
synchronized by nocodazole, were incubated with 2 mM prop-Cho for 2 h. The cells were fixed and processed for immunofluor-
escence with Alexa 488-azide (a) and Cy3 conjugated anti-Mouse (for lamin A/C) (b) and analyzed by confocal microscopy (Olympus
FV1000 microscope). (c) merged; (d) bright field.
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Supplemental Figure 5 and Supplemental Table 1.
HeLa cells were very sensitive to the antimetabolite
5-fluorouracil, but did not show a dose-response cor-
relation over a wide range of concentrations
(Supplemental Table 1) curtailing its use for com-
bined treatment. On the contrary, staurosporine did
not elicit a strong effect at doses that induce apoptosis
in other cell lines but showed a dose-response correla-
tion. The simultaneous treatment with staurosporine
and C75 showed an additive or antagonistic effect
(Supplemental Table 2). Twenty-four hour treatment
with etoposide (80 μM) alone decreased total cell
number by ~30–50% (Figure 8(a)) with only a slight
increase in apoptosis (as assessed by cleaved PARP,
data not shown). As previously reported for HeLa
cells, etoposide induced G2/M arrest, evidenced by
increased cyclin B1 (Figure 8(c)). At low doses, simul-
taneous treatment with etoposide and C75 showed
amoderate synergistic effect (Combination index < 1)
(Figure 8(b) and Table 1). Although the fraction
affected was low, the combination produced
a decrease in cell number at 10 μg/ml C75, a dose
that did not elicit an effect as a single agent. At higher
doses, the combined effect was additive or antagonis-
tic. Accordingly, simultaneous silencing of FASN and
etoposide treatment showed no synergy on cell cycle
arrest (assessed by cyclin B1 accumulation) (Figure 8
(c)). Unexpectedly, etoposide reduced the level of
FASN. Etoposide treatment was shown to increase
FASN promoter-reporter activity in breast cancer
cells [38]. Since FASN is highly regulated at multiple
levels, including protein stability [39], further studies
will be needed to assess the mechanism(s) by which
etoposide regulates FASN and whether it explains the
complex response to combined treatment with FASN
inhibitors. Thus, although at high doses combined
drugs may show an antagonistic effect, our results
suggest that the effect of FASN inhibition may be





Figure 5. Impaired de novo PtdCho synthesis does not affect cell cycle progression. HeLa cells were transfected with siRNAs
targeting CTα or a Non-Targeting pool (NT) at 10 nM for 48 h. The levels of CTα, Cyclin B1 and Vinculin were estimated by Western
Blot (a). The level on CTα (b) and cell cycle distribution (d) were assessed in HeLa cells transfected with siRNA targeting CTα (hCTα4)
or NT 10 nM for 48 h and incubated for 1 h with 10 μM BrdU. Alternatively, NT and hCTα4-siRNA transfected cells were incubated
with [Methyl-3H]choline for 4 h. Aqueous metabolites were resolved by TLC and scrapped off and counted. CTα activity was
estimated by the ratio of radiolabeled CDP-Choline/phospho-choline (c). Ct: untransfected cells.
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Discussion
The requirements and regulation of membrane
lipid metabolism during the cell cycle is poorly
understood. We have previously reported that
extensive changes in lipid metabolism occur as
the cells complete the cell cycle [19], but the fate
and importance of each lipid is unknown. Here we
show that de novo synthesized FA at the mitotic
exit are used for phospholipid synthesis and incor-
porated mainly in the NE, suggesting that they are
required for its reassembly and/or expansion.
Moreover, we show that, as reported in different
models [40,41], endogenous synthesis of PtdCho is
also used for nuclear/ER membrane production at
the mitotic exit. The importance of lipids for NE
dynamics in open mitosis is starting to emerge.
Thus, it has been reported that NE breakdown is
regulated by specific lipid signals [42–45]. There is
also evidence that some proteins that control the
cell cycle exit regulate lipid synthesis. For instance,
the ER lipid raft-associated 2 (ERLIN2) protein
regulates both the mitotic cyclin B1 and lipid
synthesis [46–48]. Similarly, the tumour suppres-
sor BRCA1 (breast cancer susceptibility gene 1)
controls G2/M checkpoint [49] and de novo FA





Figure 6. Impaired lysophospholipid acylation does not cause cell cycle arrest at G2/M phase. (a) HeLa cells were incubated with CI-
976 (lysophospholipid acyltransferases inhibitor) for 24 h in FBS-depleted media at 0, 0.02, 0.1, 0.5, 2.5 y 12.5 μM. Proliferation was
estimated by Crystal Violet staining. (b) HeLa cells were incubated with 2.5 μM CI-976 o vehicle (0.01% DMSO) (without FBS) for 24 h.
Two hours before harvesting the cells were incubated with [14C] LysoPtdCho −0.5% FA free BSA for 2 h. Total lipids were resolved by
TLC and PtdCho and LysoPtdCho were scrapped off the plate and counted in by liquid scintillation counting. (c) Cell cycle profile and
apoptosis (d) were estimated by flow cytometry or cleaved PARP (cPARP) and Cyclin B1 content by Western Blot, respectively after
24 h incubation with 2.5 μM CI-976. * p < 0.05 CI-976 vs control.
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suggests that mitosis/cytokinesis are not as meta-
bolically inactive as previously thought.
To study further the importance of the observed
changes in lipid metabolism and to identify the lipid-
(s) necessary for cell cycle completion, we impaired
different enzymatic steps in lipogenic routes. As we
reported previously, reduced de novo FA synthesis
arrested the cells at G2/M [19,51]. Surprisingly,
although FA were used for PtdCho generation and
newly synthesized PtdCho is increased at the mitotic
exit [19], no arrest was observed upon knockdown of




Figure 7. Simultaneous inhibition of PtdCho synthesis and lysophospholipid acylation induces apoptosis and G2/M arrest. HeLa cells
were incubated with edelfosine at the indicated concentrations for 24 h. Total cell number and viability (a) were estimated in
hemocytometer with Trypan Blue. Apoptosis and cell cycle distribution were assessed by Cyclin B1 levels by Western Blot (b) or flow
cytometry (c). * p < 0.05 2.5 μM vs control.
a b c
Figure 8. Combined effect of etoposide and FASN impairment. Hela cells were treated with etoposide 80 μM for 24 h and the total
cell number was estimated (a). The cells were incubated with etoposide and C75 at the concentrations shown in Table 1. The fraction
affected and combination index were calculated as described under Methods (b). siRNA FASN or NT-transfected cells were incubated
with etoposide 80 μM for 24 h and the FASN and cyclin B1 contents were assessed by Western Blot using vinculin as loading control.
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mutant cells CHO-MT58, which harbours
a temperature sensitive mutation on the CT gene.
Even at undetectable CT levels [52] mutant cells are
viable and proliferative for several days at the restric-
tive temperature [53]. Although, under specific
genetic backgrounds, CT deficiency induces poly-
ploidy [54], we have not seen changes in the cell
cycle distribution in CHO-MT58 (a kind gift of
Dr Claudia Kent Dixon) upon 24 h growth at the
restrictive temperature (unpublished observations).
Moreover, heterozygous mice (CTα+/-), with 50%
CTα activity are viable and have no major phenotype
[55]. Thus, alternative pathways may provide enough
PtdCho to support cell growth and proliferation. One
such a route may be LysoPtdCho acylation [35].
Indeed, there is some evidence that LysoPtdCho acy-
lation may contribute to PtdCho synthesis at the
mitotic exit [8,19]. Our results showed that the simul-
taneous inhibition of both PtdCho synthesis and lyso-
phospholipid acylation (but not either alone) arrests
cells at G2/M. Importantly, this suggests that it is the
supply of PtdCho and not the reduction of a specific
precursor that is necessary to complete the cell cycle.
Combined, our previous and current studies would
indicate that cells are more sensitive to the inhibition
of FASN than to alterations in PtdCho metabolism. It
is still unknown why exogenous FA are unable to
support cell proliferation and survival upon FASN
inhibition.
FASN has emerged as a putative therapeutic target
for numerous cancers, but the side effects of some
inhibitors have curtailed their clinical use and only
one small molecule is currently under phase II trial
(NCT03179904 clinicaltrials.gov). The combination
of inhibitors of the cell cycle with chemotherapeutic
agents may improve therapy efficiency [56]. Thus,
the G2/M arrest induced by FASN inhibition may
enhance the effect of conventional chemotherapy.
Conversely, the use of chemotherapy may increase
the effect of FASN inhibitors and, thus, reduce their
side effects. Indeed, we found a moderate synergistic
effect at low doses of C75 and etoposide. At high
doses, however, etoposide (and staurosporine)
showed an antagonistic effect with C75. This com-
plex response has also been observed when combin-
ing etoposide with other inhibitors [57]. It is to be
determined whether a different schedule of admin-
istration may improve the efficacy of the combined
treatment.
Overall, our results suggest that newly synthe-
sized lipids are used for the reassembly/expansion
of the nuclear envelope upon mitosis completion.
The cells use either acylation of lysoPtdCho or the
Kennedy (diacylglycerol, DAG) pathway to pro-
vide PtdCho, but a strong dependency on de
novo synthesis of FA generates a cell cycle-related
metabolic vulnerability (Figure 9).
Table 1. Combination index for etoposide and C75.
C75 (μg/ml) Etoposide (μM)
3.93 7.85 15.7 31.4 62.8
10 0.622 0.774 0.797 1.093 1.791
20 0.941 1.042 1.191 1.453 1.779
40 0.999 1.095 1.173 1.384 1.441
Figure 9. Working model.
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